Répertoire des subventions financées

Filtrer par

562 ésultat(s) trouvé(s)

An interdisciplinary approach to mindfulness as a quality of life improvement factor for people with ALS and their primary caregivers

  • Type de programme

    Team grants

  • Domaine de recherche

    Neurodegeneration

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Québec

  • Date de Début

    2021

  • Montant total du financement

    $121,950

  • Contribution Santé Canada

    $60,975

Aperçu du projet

Mindfulness is a therapeutic technique that teaches one to focus on the present moment, while calmly acknowledging and accepting their feelings, thoughts, and bodily sensations. Previous research has demonstrated that learning mindfulness can help with navigating grief and benefit overall quality of life. In this pilot study, the first of…

Modulating the ALS-associated C9orf72 repeat expansion in a murine model for therapeutic benefit

  • Type de programme

    Team grants

  • Domaine de recherche

    Neurodegeneration

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Ontario

  • Date de Début

    2021

  • Montant total du financement

    $125,000

  • Contribution Santé Canada

    $62,500

Aperçu du projet

Mutations in a gene called C9ORF72 are the most common genetic cause of ALS. These mutations are unique in that unlike most other ALS-linked genes, where there is often a mistake in a single piece of DNA, C9ORF72 mutations involve a section of DNA that is abnormally repeated hundreds or…

Investigating the role of mutations in CHCHD10 using ALS cell and zebrafish genetic models

  • Type de programme

    Team grants

  • Domaine de recherche

    Neurodegeneration

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Québec

  • Date de Début

    2021

  • Montant total du financement

    $125,000

  • Contribution Santé Canada

    $62,500

Aperçu du projet

In 2014, mutations in a gene called CHCHD10 were newly identified as a genetic cause of ALS. Later, in 2018, co-recipient Dr. Eric Shoubridge discovered that the role of CHCHD10 in ALS is connected to another protein, called CHCHD2. The exact way in which mutations in CHCHD10 and its interaction…

Advanced pharmacokinetics and pharmacodynamics for phase Ib/IIa trial of repurposed enoxacin therapy for patients with ALS

  • Type de programme

    Team grants

  • Domaine de recherche

    Neurodegeneration

  • Disease Area

    ALS FR

  • Compétition

    Société canadienne de la SLA - Fondation Brain Canada - Bourses de découverte

  • Province

    Québec

  • Date de Début

    2021

  • Montant total du financement

    $125,000

  • Contribution Santé Canada

    $62,500

Aperçu du projet

A Phase 1/2 clinical trial led by Dr. Angela Genge and co-recipient Dr. Eran Hornstein is currently underway to test the safety and tolerability of enoxacin in people living with ALS. Enoxacin is an antibiotic that on a cellular level is known to activate an enzyme called DICER, which in…

Causal tests of the hippocampal circuits mediating neural and behavioral pattern completion

  • Type de programme

    Capacity building grants

  • Domaine de recherche

    Central Nervous System

  • Disease Area

    Other

  • Compétition

    Future Leaders in Canadian Brain Research

  • Province

    Québec

  • Date de Début

    2020

  • Montant total du financement

    $100,000

  • Contribution Santé Canada

    $50,000

Aperçu du projet

Most people have experienced the recollection of a vivid memory after encountering a trigger, such as a familiar place, object, or smell. In neuroscience, this process is called 'pattern completion'. For years people have thought that a particular part of the brain, called the ‘trisynaptic circuit’ of the hippocampus, might…